Letter from the Editors

Radionuclide bone imaging is a significant clinical procedure that has been performed since the inception of the modern era of clinical nuclear medicine a half century ago. Our very first issue of Seminars in Nuclear Medicine devoted to this subject was on January 1972 (vol. 2, no. 1).1 At that time, the most widely used agent was strontium-85. Because of the long 64-day physical half-life of strontium-85, we were restricted to a small 100  µCi dose for use only in malignant diseases. The subsequent introduction of the 99mTc-phosphate agents by Subramanian and McAfee2 not only improved diagnosis of malignant disorders but also opened new vistas in the diagnosis of benign bone disorders, including metabolic, traumatic, inflammatory, and joint diseases.
Source: Seminars in Nuclear Medicine - Category: Nuclear Medicine Authors: Source Type: research